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Abstract
Background-: Sporadic breast cancer like many other cancers is proposed to be a manifestation of abnormal
genetic and epigenetic changes. For the past decade our laboratory has identified genes involved in DNA damage
response (DDR), apoptosis and immunesurvelliance pathways to influence sporadic breast cancer risk in north
Indian population. Further to enhance our knowledge at the epigenetic level, we performed DNA methylation
study involving 17 gene promoter regions belonging to DNA damage response (DDR) and death receptor
apoptotic pathway in 162 paired normal and cancerous breast tissues from 81 sporadic breast cancer patients,
using a high throughput quantitative DNA methylation analysis technology.
Results-: The study identified five genes with statistically significant difference between normal and tumor tissues.
Hypermethylation of DR5 (P = 0.001), DCR1 (P = 0.00001), DCR2 (P = 0.0000000005) and BRCA2 (P = 0.007) and
hypomethylation of DR4 (P = 0.011) in sporadic breast tumor tissues suggested a weak/aberrant activation of the
DDR/apoptotic pathway in breast tumorigenesis. Negative correlation was observed between methylation status
and transcript expression levels for TRAIL, DR4, CASP8, ATM, CHEK2, BRCA1 and BRCA2 CpG sites. Categorization of
the gene methylation with respect to the clinicopathological parameters showed an increase in aberrant
methylation pattern in advanced tumors. These uncharacteristic methylation patterns corresponded with decreased
death receptor apoptosis (P = 0.047) and DNA damage repair potential (P = 0.004) in advanced tumors. The
observation of BRCA2 -26 G/A 5’UTR polymorphism concomitant with the presence of methylation in the promoter
region was novel and emerged as a strong candidate for susceptibility to sporadic breast tumors.
Conclusion-: Our study indicates that methylation of DDR-apoptotic gene promoters in sporadic breast cancer is
not a random phenomenon. Progressive epigenetic alterations in advancing tumors result in aberrant DDR-
apoptotic pathway thereby promoting tumor development. We propose, since pathological epigenetic changes of
the DDR-apoptotic genes are reversible modifications, these could further be targeted for therapeutic interventions.
Introduction
Breast cancer is the leading cause of cancer mortality
among women aged between 20 - 59 years; second lead-
ing cause of cancer mortality among all women [1]. The
sporadic form represents almost 90% of the total num-
ber of breast cancer cases, genetic etiology of which is
least understood and the molecular mechanism underly-
ing the onset and progression not clear. It is, however,
believed to be a manifestation of abnormal genetic as
well as epigenetic changes [2-4] along with the influence
of dietary, environmental and physical factors [5]. Pre-
vious studies from our laboratory have identified genes
involved in DNA damage response (DDR), apoptosis
and immunesurvelliance pathways such as polymorph-
isms in BRCA2, p53 [6], IFNG [7], TGFB1 [8], TRAIL
[9] and mDNA [10], somatic mutations in IL6 [11] and
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aberrant expression of DDR pathway [14] to influence
sporadic breast cancer risk in north Indian population.
Since, studies have identified de-novo methyltransferases,
DNMT3b, over-expressed in breast tumors [15], indicat-
ing an involvement of epigenetic modifications in onco-
genesis, breast cancer susceptibility genes, identified
under the categories of DNA damage response (DDR)
and apoptosis related genes could be a major target of
epigenetic inactivation in sporadic breast cancers. Also,
numerous studies have shown that large scale methyla-
tion profiling of multiple CpG sites could prove essential
to provide comprehensive information on DNA methy-
lation changes occurring during neoplastic transforma-
tion [16-24].
In cancer cells, apoptosis induced by extrinsic pathway
complements the intrinsic pathway [25]. The extrinsic
signal transduction pathway is activated by TRAIL that
binds two types of receptors: DR4/5 and DCR1/2 [25].
Binding of TRAIL to DR4 and/or DR5 results in recep-
tor oligomerization and subsequent activation of CASP8
resulting in apoptosis [26]. Similarly, CASP8 can also
activate the intrinsic apoptotic pathway causing the
release of CYCS from the mitochondria which serves to
amplify the death receptor apoptotic signal [26]. On the
contrary, decoy receptors, FLIP and BCL2 block the
apoptotic signal transduction and promote survival
[25,27]. Recent studies have also identified the involve-
ment of death receptors in activating the DNA damage
response (DDR) pathway. The activation of ATM,
CHEK2 and H2AX in response to TRAIL acts as a posi-
tive feedback loop involving the activation of caspases
[28,29]. Additionally, RNF8 ubiquitinates H2AX thus,
enhancing its activation [30]. H2AX, ATM and/or
CHEK2 result in phosphorylation and activation of P53
and regulating DNA repair as well as apoptosis [31].
Although P53 is not essential for TRAIL mediated apop-
tosis [32,33], it can cause transcriptional induction of
pro-apoptotic genes such as TRAIL, DR4, DR5 [34-36]
and antagonize pro-survival genes, FLIP and BCL2
[37,38]. Further, acetylation of P53 by TIP60, also
known as KAT5 promotes apoptosis by preferentially
transactivating pro-apoptotic genes [39]. Moreover,
DNA damage response also results in activation of
BRCA1 and BRCA2 that are involved in the repair of
damaged DNA [40] (Figure 1).
Although, several methylation studies have been car-
ried out for DR4, DR5, DCR1, DCR2, CASP8, TP53,
BRCA1 and BRCA2 in various types of cancer, none of
them provide a holistic view of the DDR - apoptotic
pathway [21,41-45]. Therefore, after investigating the
breast tumor at the genetic and expression level, we for
the first time provide an integrated information on
methylation patterns of the DDR and death receptor
apoptotic pathway genes (TRAIL, DR4, DR5, DCR1,
DCR2, CASP8, FLIP, BCL2, CYCS, ATM, TP53, BRCA1,
BRCA2, H2AX, RNF8, TIP60 and CHEK2)i ns p o r a d i c
breast tumors, using high throughput automated
MALDI TOF [17-19,22]. The study further dissects the
role of methylation of candidate genes in sporadic breast
tumorigenesis, its interaction with functional BRCA2 -26
SNP and the status of pro- and anti- apoptotic as well
as DNA damage repair gene expression in breast tumor
tissues.
Materials and methods
Samples
A total of 162 tissue samples (81 ductal carcinoma tis-
sues and 81 adjacent normal tissues, both of parenchy-
mal origin) were collected from 81 patients with
sporadic breast cancer from Dharamshila Cancer Hospi-
tal and Research Centre, New Delhi; Rajiv Gandhi
Cancer Institute and Research Center, New Delhi and
Sanjay Gandhi Postgraduate Institute of Medical
Sciences, Lucknow. The study samples adhered to the
REMARK guidelines [46]. The female patients ranged in
t h ea g eg r o u po f2 5t o7 7y e a r s ,w i t ham e d i a no f4 8
years. None of the studied cases had a hereditary form
of breast cancer. Prior approval was obtained from Jawa-
harlal Nehru University ethical committee and the
informed consent taken of the concerned subjects for
sample collection and study.
Differentiation between cancerous and normal tissue
was based on magnetic resonance imaging, intra-
operative gross surgical pathology and tissue histology.
Breast tumor patients underwent imaging (mammogra-
phy, ultra-sonography and MRI) to know the location,
size and extent of tumor. Tumor was removed wide of
its margin i.e. 1-2 cm envelope of normal breast tissue
was left all around the tumor to ensure removal of any
microscopic extensions of the tumor into normal breast
parenchyma. What we considered as normal tissue was
taken 2 cm away from the palpable tumor margin. This
fact was further confirmed by frozen section histology
and paraffin section histology before labeling the tumor
and normal tissues for molecular biology experiments,
thereby ensuring the absence of cross contamination.
Patients were classified on the basis of tumor size,
nodal status, tumor stage, estrogen and progesterone
receptor (ER and PR) status. At the time of diagnosis, 7
patients had stage I disease, 44 patients belonged to
stage II, 28 patients to stage III and 2 patients had stage
IV disease. ER/PR status and tumor grade could be
obtained for 57 out of 81 pairs of tumor tissues studied.
Immunohistochemical staining identified 27/24 ER/PR
positive patients and 30/33 ER/PR negative patients.
Out of 57 patients, 2 patients had grade I tumor, 30 had
grade II tumor and 25 had grade III tumor (Additional
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immediately and stored at -80°C until use. DNA extrac-
tion was performed from 0.01 - 0.02 g of tissue sample,
using the Genelute Mammalian genomic DNA isolation
kit (Sigma Aldrich, St. Louis, Missouri, USA).
Bisulfite treatment and PCR
The EZ-96 DNA Methylation Kit (Zymo Research,
Orange, CA, USA) was used for bisulfite conversion of
the target sequences. The C/T conversion reaction was
performed using the PCR program as follows: 95°C for
30 sec and 50°C for 15 min, which was repeated for 46
cycles. Primers were designed using epidesigner software
(Sequenom, San Diego, CA, USA) to cover the regions
with the most CpG sites (Additional file 2, Table S2).
Our selected amplicons were mostly located in the pro-
moter region of genes or started from the promoter and
ended in the first exon. In PCR amplification, a T7-pro-
moter tag was added to the reverse primer and a 10
mer-tag sequence was added to the forward primer to
balance the PCR primer length. The bisulfite treated
genomic DNA was amplified using Taq DNA polymer-
ase (Roche Diagnostics, Mannheim, Germany) (4 min at
95°C followed by 45 cycles of 20 sec at 95°C, 30 sec at
Figure 1 Crosstalk between DNA damage response and Death Receptor apoptotic pathways.
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sion). PCR products were analyzed further in Sequenom
MassARRAY. Methylated and unmethylated positive
control human DNA was procured from Sequenom.
Fully methylated DNA was mixed with pure unmethy-
lated DNA in a ratio of 100:0, 60:40, 40:60, and 0:100.
In vitro transcription, T cleavage assay and Mass
Spectrometry
Unincorporated dNTPs were dephosphorylated by add-
ing 1.7 μlH 2O and 0.3U shrimp alkaline phosphatase
(Sequenom) followed by incubation at 37°C for 40 min
and heat inactivation of shrimp alkaline phosphatase at
85°C for 5 min. In general, 2 μl of the PCR was directly
used as a template in a 5 μl transcription reaction. T7
RNA and DNA Polymerase (20U) (Sequenom) was used
to incorporate dTTP in the transcripts. Ribonucleotides
were used at 1 mmol/l and the dNTP substrate at 2.5
mmol/l. RNaseA enzyme (Sequenom) was added in the
same step to cleave the in vitro transcripts (T-cleavage
assay). The T cleavage reaction was carried out at 37°C
for 3 hours and further diluted with H2Ot oaf i n a l
volume of 27 μl. Conditioning of the phosphate back-
bone was achieved by adding 6 mg of Clean Resin
(Sequenom) before performing MALDI-TOF MS.
22 nl of cleavage reaction was robotically dispensed
onto a silicon matrix preloaded chips (SpectroCHIP;
Sequenom), and the mass spectra obtained using a
MassARRAY. Methylation ratios were generated by the
MALDI-TOF and EpiTYPER software v1.0 (Sequenom).
The assay was able to discriminate between the methy-
lated and unmethylated components of the positive
control according to the ratios.
Genotype and Expression Analysis
Sequence based analysis of the amplified 5’UTR region
of the BRCA2 gene as described earlier [6] for genotype
status was performed for 81 samples in which methyla-
tion study was carried out. Commercially available Taq-
m a nG e n ee x p r e s s i o nA s s a ys ystem for quantitating
transcript level of TRAIL, DR4, DR5, DCR1, DCR2,
CASP8, CASP8L, FLIPL, FLIPS, BCL2, CYCS, ATM,
TP53, BRCA1, BRCA2, CHEK2 [9,14] and H2AX
(Hs01573336_s1) genes belonging to the DDR and
apoptotic pathway were used for studying mRNA
expression in 40 representative tumor samples out of
the 81 paired normal/tumor samples used in methyla-
tion study (Applied Biosystems, Foster City, CA, USA).
GAPDH, B-Actin, PUM1,a n dMRPL19 (Applied Biosys-
tems) were used as endogenous controls [9]. Quantita-
tive real-time PCR was carried out using an ABI Prism
7900 Sequence Detection System (Applied Biosystems).
Threshold cycle (Ct) numbers were established by using
SDS 1.1 RQ software (Applied Biosystems). All the
reactions were carried out in duplicates. The normaliza-
tion factor obtained from GeNorm software was used to
compute normalized expression for the target genes [9].
Categorization of the results was done on the basis of
pro- versus anti- apoptotic genes involved in death
receptor apoptotic pathway [(TRAIL + DR4 + DR5 +
CASP8 + ATM + H2AX + CHEK2 + CYCS)/(DCR1 +
DCR2 + CASP8L + FLIPL + FLIPS + BCL2)] and DNA
damage response pathway [ATM + CHEK2 + BRCA1 +
BRCA2 + H2AX]. Earlier studies from our laboratory
have shown that higher level of P53 expression in
advanced breast tumors did not reflect in P53 activity in
later stages of tumor development [14] and thus was
not considered while calculating the DNA damage
response signal.
Statistical Methods
Relative methylation was compared using the Wilcoxon
signed-rank test, a nonparametric counterpart of the
paired t-test to identify sites with statistically significant
difference, between cancerous and paired normal tissues.
Using the two-way hierarchical cluster analysis, the CpG
fragments for each gene were clustered based on pair-
wise Euclidean distances and linkage algorithm for all of
the 81 pairs of tissue samples. Clustering of CpG units
were plotted along the y axis and samples along the x
axis. The procedure was carried out using the heatmap.2
function of the ‘gplots’ package using the R statistical
software. Comparison of methylation between tumor and
normal group was performed using Mann-Whitney U
test for two groups http://udel.edu/~mcdonald/statkrus-
kalwallis.html. Fisher’s exact test and Spearman’s correla-
tion coefficient was calculated using the SPSS statistical
package, version 13 (SPSS Inc., Chicago, IL, USA).
P value was considered significant at and below ≤ 0.05.
Results
Semiquantitative methylation profiles of 17 genes in
cancerous and normal tissue
In this study, we analyzed the methylation patterns of 17
breast cancer genes in 162 (cancerous and normal)
breast tissues from 81 breast tumor patients. For the 17
genes, one amplicon per gene was analyzed and the
median amplicon length was 427 bp (range = 265-496
bp). In total we assessed 492 CpGs per sample with a
total of 79,704 CpGs in 81 pairs of samples. We
removed those CpG sites that could not be detected by
MALDI-TOF MS and did not yield successful measure-
ments because of generation of higher and lower mass
fragments. CpGs which gave good results for > 90% of
the samples were considered; these consisted of 227
CpGs per sample (139 CpG sites or units) equivalent to
36,774 CpGs in 81 pairs of samples equating to 46.14%
of the total CpGs (Additional file 3, Table S3).
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value of < 5% methylation; 25% showed 5%-10% methy-
lation and the remaining 16% displayed 10%-30% methy-
lation. However, none of the normal tissues studied
showed > 30% methylation, suggesting a lower level of
methylation in our study group for the candidate genes
(Figure 2a). This was in agreement with previous finding
for normal tissue samples [18]. Mann-Whitney U test
showed average methylation to be significantly higher in
tumors whose paired counterpart belonged to the mean
methylation group of 5%-10% (P = 0.009). Moreover,
average methylation turned out to be highly significant
on comparison of whole sporadic breast tumor group
with the normal group (P = 6.272 × 10
-20) (Figure 2b).
Wilcoxon signed rank test followed by Benjamini
Hochberg correction for individual CpG sites identified
the sites that showed statistically significant difference
between normal and tumor samples (P ≤ 0.05) (Table
1). Tumor tissue showed hypomethylation for DR4,
FLIP,a n dRNF8 and hypermethylation for DR5, DCR1,
DCR2, CASP8, CYCS, BRCA1, BRCA2,w h e r e a sH2AX,
TRAIL, BCL2, ATM, CHEK2, TP53 and TIP60 did not
show any significant difference between the breast
tumor and the corresponding normal tissues.
Figure 2 Binned CpG units and differential methylation.(A) CpG sites/units binned on the basis of their average methylation value. Each bin
contained amplicon within a 5% range of methylation values. Lower bins contained more CpGs in the set of 81 normal breast tissue (B)
Differential methylation in normal vs. tumor samples across different mean methylation groups based on binning of normal samples. P value
was obtained using Mann-Whitney U test for two groups. Note: X - Axis represents groups of mean methylation obtained in normal tissue
samples for the study population. For each of the 139 CpG units, the methylation values for the 81 normal tissues were added to obtain mean
methylation values. These were then divided into groups of 0% - 5%, 5% - 10%, 10% - 15%, 15% - 20%, 20% - 25% and 25% - 30%.
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to the transcription start site (TSS) revealed their pre-
sence in the promoter, 5’UTR, coding exon 1 and/or
intron1-2 regions.
Further, unsupervised two-way hierarchical clustering
with 139 CpG sites/units in 81 pair of samples showed
separate grouping of normal and breast tumor samples
with negligible intermixing (Figure 3) as confirmed by
Fisher’s exact test (P = 0.00000001) (Table 2). We again
performed unsupervised two-way hierarchical clustering
for the 33 CpG units that were found to be significant
after supervised clustering in Wilcoxon test and
Table 1 Wilcoxon signed rank test showing methylation status between breast tumor and adjacent normal tissue
SR. NO. GENE CpG SITE; N = 81 NOR - TUM PAIRS P
a P
b METHYLATION STATUS LOCATION
1 DR4 18.19 (-35,-39) 0.010 0.041 Hypomethylation Promoter
2 DR4 20.21 (-89,-93) 0.007 0.033 Hypomethylation Promoter
3 DR4 23 (-111) 0.009 0.041 Hypomethylation Promoter
4 DR4 24 (-137) 0.018 0.069 Hypomethylation Promoter
5 DR5 11 (-149) 0.006 0.031 Hypermethylation Promoter
6 DR5 27 (-363) 0.040 0.149 Hypermethylation Promoter
7 DR5 28.29 (-374,-376) 0.0003 0.003 Hypermethylation Promoter
8 DCR1 4.5.6 (-17,-12,-7) 0.0002 0.002 Hypermethylation Promoter
9 DCR1 11 (+100) 0.0004 0.003 Hypermethylation 5’UTR
10 DCR1 12 (+110) 0.0003 0.002 Hypermethylation 5’UTR
11 DCR1 13.14.15 (+134,+139,+143) 0.0002 0.001 Hypermethylation 5’UTR
12 DCR1 16 (+154) 0.001 0.008 Hypermethylation 5’UTR
13 DCR1 17 (+166) 0.000008 0.0001 Hypermethylation 5’UTR
14 DCR1 18.19.20 (+183,+186,+189) 0.000001 0.00002 Hypermethylation 5’UTR
15 DCR1 22.23.24 (+231,+234,+237) 0.0001 0.001 Hypermethylation Ex1 coding
16 DCR1 25.26.27 (+243,+246,+248) 0.0003 0.002 Hypermethylation Ex1 coding
17 DCR1 32.33 (+306,+309) 0.00002 0.0002 Hypermethylation Int 1-2
18 DCR1 34 (+327) 0.009 0.041 Hypermethylation Int 1-2
19 DCR2 1 (+169) 0.0000007 0.00001 Hypermethylation Ex1 coding
20 DCR2 2 (+166) 0.0000006 0.00001 Hypermethylation Ex1 coding
21 DCR2 7.8 (+122,+118) 0.0000000007 0.00000005 Hypermethylation Ex1 coding
22 DCR2 12.13 (+44,+38) 0.0000000003 0.00000004 Hypermethylation 5’UTR
23 DCR2 16 (+11) 0.0000001 0.000003 Hypermethylation 5’UTR
24 DCR2 17.18 (-14,-24) 0.0000002 0.000006 Hypermethylation Promoter
25 DCR2 19 (-37) 0.0000003 0.000007 Hypermethylation Promoter
26 DCR2 20 (-48) 0.000000002 0.00000006 Hypermethylation Promoter
27 DCR2 24 (-178) 0.0000000008 0.00000004 Hypermethylation Promoter
28 CASP8 2.3 (+532,+537) 0.000009 0.0001 Hypermethylation Int 1-2
29 CASP8 6 (+635) 0.048 0.176 Hypomethylation Int 1-3
30 FLIP 18.19.20.21 (+319,+326,+328,+332) 0.001 0.008 Hypomethylation Int 1-4
31 CYCS 17.18 (+59,+62) 0.001 0.008 Hypermethylation 5’UTR
32 CYCS 19.20.21 (+89,+93,+99) 0.003 0.016 Hypermethylation 5’UTR
33 TP53 6 (-16) 0.017 0.067 Hypermethylation Promoter
34 BRCA1 16 (-251) 0.005 0.025 Hypermethylation Promoter
35 BRCA1 17 (-234) 0.016 0.065 Hypermethylation Promoter
36 BRCA2 32.33 (-6,-8) 0.008 0.038 Hypermethylation Promoter
37 RNF8 9.10.11.12 (-69,-67,-63,-58) 0.0001 0.001 Hypomethylation Promoter
38 H2AX 3 (-326) 0.002 0.013 Hypermethylation Promoter
CpG site positions are mentioned with respect to the transcription start site. P
a value for Wilcoxon signed-rank test between breast tumor and adjacent normal
tissue. P
b value for Wilcoxon signed-rank test between breast tumor and adjacent normal tissue after Benjamini Hochberg correction - significant values shown in
bold.
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tion was observed in the normal samples as compared
to tumor samples (Additional file 4, Figure S1).
Mean methylation values (sample-wise average of
methylation values of all CpG sites in one gene)
reflected that DR5, DCR1, DCR2 and BRCA2 were
hypermethylated whereas DR4 was hypomethylated in
tumors as compared to adjacent normal tissues (Figure
4). Genes that did not show any difference between
mean methylation pattern of normal and tumor tissues
were: T R A I L ,B C L 2 ,C A S P 8 ,C Y C S ,F L I P ,A T M ,T P 5 3 ,
CHEK2, RNF8, TIP60, H2AX and BRCA1.
Clinicopathological association
In order to understand the role of methylation in tumor
progression, we compared the differential methylation
pattern observed in normal versus tumor samples with
respect to the various clinicopathological parameters
(Table 3). ER negative tumors showed hypermethylation
of DCR2 (87%; P = 0.00007) and hypomethylation of
DR4 (77%; P = 0.001). Hypermethylation of DCR2 (75%;
p = 0.001) in PR positive cases, hypomethylated DR4
(79%; p = 0.0002), hypermethylated DCR1 (64%; P =
0.004) and DCR2 (85%; P = 0.00003) in PR negative
tumors was observed even after Benjamini Hochberg
correction. Node negative tumors showed hypermethyla-
tion of DCR1 (63%; P = 0.003) and DCR2 (83%; P =
0.00001) while node positive displayed hypermethylation
of DCR1 (66%, P = 0.001), DCR2 (73%; P = 0.00001)
Figure 3 Heatmap showing separate clustering of breast tumor (red) and normal (green) samples.
Table 2 Fisher’s exact test for validation of the presence
of distinct tumor and normal groups based on
methylation status of the DNA damage response and
death receptor apoptotic pathway genes
Tumor/Normal group Tumor
(N = 81)
Normal
(N = 81)
P
a
Tumor group (N = 62) 49 (79.03%) 13 (20.96%)
Normal group (N = 100) 32 (32.00%) 68 (68.00%) 0.00000001
P
a value for Fisher’s exact test.
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and 2 showed hypermethylation of DR5 (68%; P =
0.002), DCR1 (63%; P = 0.001) and DCR2 (80%;
P = 0.0000001) as well as hypomethylation of DR4 (58%;
P = 0.011), FLIP (61%; P = 0.007) and ATM (59%; P =
0.013) after Benjamini Hochberg correction. Similarly,
tumor size 3 and 4 in combination showed hypermethy-
lation of DCR1 (68%; P = 0.002) and DCR2 (73%; P =
0.001). Together, stage I and II tumors displayed hyper-
methylation of DCR1 (61%; P = 0.003) and DCR2 (82%;
P = 0.000001), although hypomethylation was observed
in some of the candidates but lost after Benjamini
Hochberg correction. Likewise, stage III and IV tumors
jointly showed hypermethylation in DCR1 (70%; P =
0.001) and DCR2 (70%; P = 0.0002) and BRCA2 (57%;
P = 0.005). Grade I and II tumors exhibited hyper-
methylation in DCR2 (78%; P = 0.0002) while grade III
tumors displayed DR5 (64%; P = 0.006), DCR1 (68%; P
= 0.007) and DCR2 (84%; P = 0.0001) hypermethylation,
and hypomethylation of DR4 (84%; P = 0.0003) and
RNF8 (72%; P = 0.010).
Real time expression analysis of DDR - apoptotic pathway
genes and their correlation with the methylation pattern
In order to understand the level of DNA damage repair
and apoptosis with respect to tumor progression, a repre-
sentative set of 40 tumor samples were studied for the real
time expression of 15 genes (TRAIL, DR4, DR5, DCR1,
DCR2, CASP8, CASP8L, FLIPL, FLIPS, BCL2, CYCS, ATM,
TP53, BRCA1, BRCA2, CHEK2 and H2AX)b e l o n g i n gt o
the DDR and apoptotic pathway. The results of expression
for these genes were categorized in pro- apoptotic versus
anti- apoptotic signals and DNA damage response signals
with respect to the tumor stages. The results showed that
DNA damage response as well as apoptosis decreased with
advancing sporadic breast tumors (P = 0.004; 0.047) (Fig-
ure 5) (Additional file 5, Figure S2).
Also, the relationship between promoter methylation
and gene expression was evaluated. Spearman’sc o r r e l a -
tion coefficient was calculated for each CpG unit. Nega-
tive correlation was observed for TRAIL -116 (P =
0.013; r = -0.350), DR4 +108 (P = 0.025; r = -0.331),
CASP8 +571 (P = 0.046; r = -0.271), ATM -369 (P =
0.046; r = -0.270), ATM -314, -310 (P = 0.034; r =
-0.291), CHEK2 -396, -393 (P = 0.040; r = -0.281),
BRCA1 -314 (P = 0.030; r = -0.300), BRCA1 -251 (P =
0.004; r = -0.410), BRCA2 -101 (P = 0.036; r = -0.288)
and BRCA2 +133, +136, +138 (P = 0.023; r = -0.318).
However, positive correlation was observed for DR4
+23, +25, +28, +32 (P = 0.017; r = 0.335) and CYCS
+241, +243 (P = 0.048; r = 0.266) (Table 4). On other
hand, no correlation was observed for DR5, FLIP, BCL2,
TP53 and H2AX. Insilico analysis using Alibaba2.1
revealed the presence of Sp1, ER and GBF2 transcription
factor (TF) binding sites or absence of TF consensus
sequence at these positions.
Figure 4 Box plot showing mean methylation pattern between normal and tumor samples for the 17 genes studied. Bottom and top
of the box are the 25
th and 75
th percentile (the lower and upper quartiles, respectively), and the band near the middle of the box is the 50
th
percentile (the median). The ends of the whiskers represents 5
th and 95
th percentile whereas data that are not included within these whiskers
are plotted as an outlier (dot). * represent significant difference between normal and adjacent tumor samples. ** represent significant difference
between normal and adjacent tumor samples after Benjamini Hochberg correction.
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Page 8 of 16Table 3 Comparison of mean methylation between normal and tumor samples for the 17 genes studied with respect
to the various clinicopathological parameters
CLINICOPATHOLOGICAL PARAMETERS TRAIL DR4 DR5 DCR1 DCR2 CASP8 FLIP BCL2 CYCS
ER+ (N = 27) 13
a,1 4
b,0
c 11, 15, 1 8, 16, 3 6, 21, 0 6, 20, 1 12, 15, 0 14, 11, 2 18, 9, 0 14, 13, 0
PERCENTAGE (%) 48
a,5 2
b,0
c 41, 56, 4 30, 59, 11 22, 78, 0 22, 74, 4 44, 56, 0 52, 41, 7 67, 33, 0 52, 48, 0
P
a 0.857 0.741 0.137 0.007 0.004 0.791 0.115 0.095 0.81
P
b 0.911 1.050 0.388 0.060 0.068 0.961 0.391 0.404 0.918
ER- (N = 30) 11, 14, 5 23, 7, 0 10, 20, 0 12, 18, 0 4, 26, 0 10, 18, 2 17, 13, 0 10, 20, 0 11, 19, 0
PERCENTAGE (%) 37, 47, 17 77, 23, 0 33, 67, 0 40, 60, 0 13, 87, 0 33, 60, 7 57, 43, 0 33, 67, 0 37, 63, 0
P
a 0.228 0.001 0.010 0.013 0.00007 0.057 0.41 0.026 0.053
P
b 0.298 0.009 0.057 0.055 0.001 0.108 0.498 0.074 0.113
PR+ (N = 24) 11, 13, 0 8, 15, 1 7, 16, 1 6, 18, 0 6, 18, 0 11, 13, 0 13, 9, 2 16, 8, 0 11, 13, 0
PERCENTAGE (%) 46, 54, 0 33, 63, 4 29, 67, 4 25, 75, 0 25, 75, 0 46, 54, 0 54, 38, 8 67, 33, 0 46, 54, 0
P
a 0.989 0.196 0.063 0.015 0.001 0.977 0.123 0.157 0.310
P
b 0.989 0.370 0.268 0.128 0.017 1.038 0.418 0.445 0.479
PR- (N = 33) 13, 15, 5 26, 7, 0 11, 20, 2 12, 21, 0 4, 28, 1 11, 20, 2 18, 15, 0 12, 21, 0 14, 19, 0
PERCENTAGE (%) 39, 45, 15 79, 21, 0 33, 61, 6 36, 64, 0 12, 85, 3 33, 61, 6 55, 45, 0 36, 64, 0 42, 58, 0
P
a 0.36 0.0002 0.019 0.004 0.00003 0.082 0.325 0.098 0.180
P
b 0.437 0.002 0.081 0.023 0.001 0.232 0.425 0.238 0.306
NODE- (N = 40) 19, 20, 1 20, 18, 2 11, 27, 2 15, 25, 0 6, 33, 1 18, 21, 1 25, 14, 1 20, 19, 1 15, 25, 0
PERCENTAGE (%) 48, 50, 3 50, 45, 5 28, 68, 5 38, 63, 0 15, 83, 3 45, 53, 3 63, 35, 3 50, 48, 3 36, 63, 0
P
a 0.828 0.162 0.011 0.003 0.00001 0.267 0.107 0.581 0.021
P
b 0.828 0.275 0.062 0.026 0.0002 0.378 0.202 0.658 0.071
NODE+ (N = 41) 21, 16, 4 27, 14, 0 14, 25, 2 14, 27, 0 10, 30, 1 13, 26, 2 20, 19, 2 21, 20, 0 18, 23, 0
PERCENTAGE (%) 51, 39, 10 66, 34, 0 34, 61, 5 34, 66, 05 24, 73, 2 32, 63, 5 49, 46, 5 51, 49, 0 44, 56, 0
P
a 0.276 0.017 0.039 0.001 0.00001 0.032 0.165 0.564 0.496
P
b 0.469 0.072 0.095 0.006 0.0002 0.091 0.312 0.685 0.703
T1 + T2 (N = 59) 33, 23, 3 34, 23, 2 16, 40, 3 22, 37, 0 11, 47, 1 23, 34, 4 36, 20, 3 33, 26, 0 27, 32, 0
PERCENTAGE (%) 56, 39, 5 58, 39, 3 27, 68, 5 37, 63, 0 19, 80, 2 39, 58, 3 61, 34, 5 56, 44, 0 46, 54, 0
P
a 0.185 0.011 0.002 0.001 0.0000001 0.068 0.007 0.213 0.077
P
b 0.262 0.037 0.011 0.009 0.000002 0.116 0.030 0.279 0.119
T3+T4 (N = 22) 7, 13, 2 13, 9, 0 9, 12, 1 7, 15, 0 5, 16, 1 8, 13, 1 9, 13, 0 8, 13, 1 6, 16, 0
PERCENTAGE (%) 32, 59, 9 59, 41, 0 41, 55, 5 32, 68, 0 23, 73, 5 36, 59, 5 41, 59, 0 36, 59, 5 27, 73, 0
P
a 0.321 0.495 0.204 0.002 0.001 0.217 0.884 0.073 0.194
P
b 0.496 0.647 0.495 0.017 0.017 0.461 0.884 0.310 0.550
STAGE 1+2 (N = 51) 25, 23, 3 27, 22, 2 15, 34, 2 20, 31, 0 9, 42, 0 21, 28, 2 31, 18, 2 28, 23, 0 22, 29, 0
PERCENTAGE (%) 49, 45, 6 53, 43, 4 29, 67, 4 39, 61, 0 18, 82, 0 41, 55, 4 61, 35, 4 55, 45, 0 43, 57, 0
P
a 0.692 0.032 0.011 0.003 0.000001 0.118 0.035 0.436 0.074
P
b 0.692 0.078 0.062 0.026 0.00001 0.182 0.074 0.570 0.140
STAGE 3+4 (N = 30) 15, 13, 2 20, 10, 0 10, 18, 2 9, 21, 0 7, 21, 2 10, 19, 1 14, 15, 1 13, 16, 1 11, 19, 0
PERCENTAGE (%) 50, 43, 7 67, 33, 0 33, 60, 7 30, 70, 0 23, 70, 7 33, 63, 3 47, 50, 3 43, 53, 3 37, 63, 0
P
a 0.576 0.181 0.041 0.001 0.0002 0.100 0.347 0.279 0.217
P
b 0.653 0.513 0.174 0.009 0.003 0.340 0.492 0.527 0.527
GRADE 1+2 (N = 32) 11, 19, 2 13, 18, 1 11, 20, 1 10, 22, 0 7, 25, 0 15, 17, 0 17, 13, 2 14, 18, 0 15, 17, 0
PERCENTAGE (%) 34, 59, 6 41, 56, 3 34, 63, 35 31, 69, 0 22, 78, 0 47, 53, 0 53, 41, 6 44, 56, 0 47, 53, 0
P
a 0.085 0.681 0.088 0.009 0.0002 0.793 0.153 0.575 0.278
P
b 0.361 0.827 0.299 0.077 0.003 0.899 0.434 0.815 0.675
GRADE 3 (N = 25) 13, 9, 3 21, 4, 0 7, 16, 2 8, 17, 0 3, 21, 1 7, 16, 2 14, 11, 0 14, 11, 0 10, 15, 0
PERCENTAGE (%) 52, 36, 12 84, 16, 0 28, 64, 8 32, 68, 0 12, 84, 4 28, 64, 8 56, 44, 0 56, 44, 0 40, 60, 0
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Page 9 of 16Table 3 Comparison of mean methylation between normal and tumor samples for the 17 genes studied with respect
to the various clinicopathological parameters (Continued)
P
a 0.353 0.0003 0.006 0.007 0.0001 0.100 0.313 0.893 0.187
P
b 0.500 0.003 0.034 0.030 0.002 0.283 0.484 0.893 0.318
CLINICOPATHOLOGICAL PARAMETERS ATM TP53 BRCA1 BRCA2 CHEK2 TIP60 RNF8 H2AX
ER+ (N = 27) 16, 11, 0 14, 10, 3 10, 17, 0 9, 14, 4 13, 10, 4 12, 14, 1 18, 9, 0 13, 11, 3
PERCENTAGE (%) 59, 41, 0 52, 37, 11 37, 63, 0 33, 52, 15 48, 37, 15 44, 52, 4 67, 33, 0 48, 41, 11
P
a 0.264 0.390 0.374 0.260 0.988 0.760 0.062 0.474
P
b 0.561 0.663 0.706 0.631 0.988 0.994 0.351 0.733
ER- (N = 30) 12, 15, 3 8, 21, 1 14, 16, 0 7, 21, 2 14, 16, 0 16, 8, 6 17, 11, 2 11, 18, 1
PERCENTAGE (%) 40, 50, 10 27, 70, 3 47, 53, 0 23, 70, 7 47, 53, 0 53, 27, 20 57, 37, 7 37, 60, 3
P
a 0.857 0.039 0.765 0.016 0.885 0.111 0.206 0.150
P
b 0.911 0.095 0.867 0.054 0.885 0.189 0.292 0.232
PR+ (N = 24) 13, 11, 0 12, 9, 3 7, 17, 0 8, 13, 3 12, 10, 2 10, 12, 2 17, 7, 0 13, 9, 2
PERCENTAGE (%) 54, 46, 0 50, 38, 13 29, 71, 0 33, 54, 13 50, 42, 8 42, 50, 8 71, 29, 0 54, 38, 8
P
a 0.658 0.519 0.174 0.192 0.974 0.858 0.039 0.298
P
b 0.860 0.735 0.423 0.408 1.104 1.042 0.221 0.507
PR- (N = 33) 15, 15, 3 10, 22, 1 17, 16, 0 8, 22, 3 15, 16, 2 18, 10, 5 18, 13, 2 11, 20, 2
PERCENTAGE (%) 45, 45, 9 30, 67, 3 52, 48, 0 24, 67, 9 45, 48, 6 55, 30, 15 55, 39, 6 33, 61, 6
P
a 0.53 0.120 0.907 0.023 0.814 0.230 0.243 0.141
P
b 0.601 0.255 0.907 0.078 0.865 0.355 0.344 0.266
NODE- (N = 40) 22, 15, 3 13, 25, 2 14, 26, 0 14, 22, 4 18, 20, 2 14, 22, 4 22, 17, 1 13, 25, 2
PERCENTAGE (%) 55, 38, 8 33, 63, 5 35, 65, 0 35, 55, 10 45, 50, 5 35, 55, 10 55, 43, 3 33, 63, 5
P
a 0.068 0.028 0.080 0.370 0.591 0.183 0.291 0.021
P
b 0.165 0.079 0.170 0.449 0.628 0.283 0.381 0.089
NODE+ (N = 41) 21, 19, 1 19, 20, 2 20, 21, 0 10, 26, 5 17, 19, 5 27, 11, 3 24, 16, 1 17, 21, 3
PERCENTAGE (%) 51, 46, 2 46, 49, 5 49, 51 24, 63, 12 41, 46, 12 66, 27, 7 59, 39, 2 41, 51, 7
P
a 0.973 0.553 0.979 0.001 0.465 0.031 0.120 0.942
P
b 1.034 0.723 0.979 0.009 0.719 0.105 0.255 1.068
T1 + T2 (N = 59) 35, 21, 3 23, 33, 3 26, 33, 0 19, 36, 4 27, 28, 4 32, 24, 3 35, 23, 1 19, 37, 3
PERCENTAGE (%) 59, 36, 5 39, 56, 5 44, 56, 0 32, 61, 7 46, 47, 7 54, 41, 5 59, 39, 2 32, 63, 5
P
a 0.013 0.407 0.694 0.056 0.639 0.276 0.037 0.040
P
b 0.037 0.461 0.694 0.106 0.679 0.335 0.090 0.085
T3+T4 (N = 22) 8, 13, 1 9, 12, 1 8, 14, 0 5, 12, 5 8, 11, 3 9, 9, 4 11. 10, 1 11, 9, 2
PERCENTAGE (%) 36, 59, 1 41, 55, 5 36, 64, 0 23, 55, 23 36, 50, 14 41, 41, 18 50, 45, 5 50, 41, 9
P
a 0.230 0.433 0.157 0.035 0.295 0.744 0.767 0.562
P
b 0.434 0.613 0.534 0.198 0.502 0.843 0.815 0.682
STAGE 1+2 (N = 51) 31, 17, 3 20, 27, 4 21, 30, 0 18, 31, 2 23, 25, 3 25, 23, 3 32, 18, 1 17, 32, 2
PERCENTAGE (%) 61, 33, 6 39, 53, 8 41, 59, 0 35, 61, 4 45, 49, 6 49, 45, 6 63, 35, 2 33, 63, 4
P
a 0.013 0.397 0.499 0.100 0.674 0.636 0.015 0.020
P
b 0.055 0.562 0.606 0.170 0.716 0.721 0.051 0.057
STAGE 3+4 (N = 30) 12, 17, 1 12, 18, 0 13, 17, 0 6, 17, 7 12, 14, 4 16, 10, 4 14, 15, 1 13, 14, 3
PERCENTAGE (%) 40, 57, 3 40, 60, 0 43, 57, 0 20, 57, 23 40, 47, 13 53, 33, 13 47, 50, 3 43, 47, 10
P
a 0.252 0.434 0.280 0.005 0.303 0.524 0.983 0.674
P
b 0.536 0.568 0.476 0.028 0.468 0.636 0.983 0.716
GRADE 1+2 (N = 32) 13, 17, 2 14, 17, 1 11, 21, 0 9, 19, 4 13, 17, 2 14, 14, 4 17, 13, 2 16, 13, 3
PERCENTAGE (%) 41, 53, 6 44, 53, 3 34, 66, 0 28, 59, 13 41, 53, 6 44, 44, 13 53, 41, 6 50, 41, 9
P
a 0.845 0.486 0.64 0.043 0.491 0.452 0.487 0.795
P
b 0.845 0.918 0.837 0.244 0.759 0.961 0.828 0.845
Pal et al. Molecular Cancer 2010, 9:303
http://www.molecular-cancer.com/content/9/1/303
Page 10 of 16Involvement of BRCA2 in sporadic breast tumor
Earlier studies from our laboratory have identified
BRCA2 -26 wild type GG and mutant AA genotype to
provide risk whereas heterozygote GA to provide protec-
tion against sporadic breast tumors [6]. Categorization of
breast tumor samples on the basis of BRCA2 -26 G/A
5’UTR polymorphism, followed by methylation status of
the candidate genes resulted in the identification of GG
and AA genotypes to be associated with hypermethylated
BRCA2 (63%;P = 0.008) ,D R 5(69%;P = 0.001),D C R 1
(67%; P = 0.0001),D C R 2(76%;P = 0.0000002), CASP8
(59%;P = 0.006) and hypomethylated FLIP (59%;P =
0.009). Whereas, the GA protector genotype was found
to be associated with hypermethylated DCR2 (81%; P =
0.0008) (Table 5). Expression data for BRCA2 transcript
compared with BRCA2 mean methylation level, revealed
a negative correlation (P = 0.033; r = -293) (Figure 6).
Discussion
Methylation alterations in cancer have been recognized
for decades [47-50]. We analyzed quantitative changes
in methylation of 17 promoter regions in 162 paired
normal and cancerous breast tissues from 81 sporadic
breast cancer patients using high throughput MALDI-
TOF MS and evaluated their distribution, correlation
and relationships to clinicopathological variables using
common statistical methods. The genes selected
belonged to the DNA damage response (DDR) and
death receptor apoptotic pathways [30,51-54]. Among
the studied 17 genes, this is the first report of promoter
methylation for CpG sites in H2AX, RNF8 and CYCS in
human cancer. The limitation of the study was our abil-
ity to score only 46.14% of the total CpG of the studied
region and the absence of screening of CpG site methy-
lation for the entire promoter and the 5’UTR.
Although methylation levels observed in breast tissues
were not very high, yet a significantly differential methy-
lation pattern existed between normal and tumor sam-
ples, suggesting that the epigenetic control of the gene
promoters was required for the maintenance of normal
cellular homeostasis, deregulation of which could result
in tumor development. Based on the DNA damage
Table 3 Comparison of mean methylation between normal and tumor samples for the 17 genes studied with respect
to the various clinicopathological parameters (Continued)
GRADE 3 (N = 25) 15, 9, 1 8, 14, 3 13, 12, 0 7, 16, 2 14, 9, 2 14, 8, 3 18, 7, 0 8, 16,1
PERCENTAGE (%) 60, 36, 4 32, 56, 12 52, 48, 0 28, 64, 8 16, 76, 8 56, 32, 12 72, 28, 0 32, 64, 4
P
a 0.141 0.494 0.686 0.114 0.523 0.648 0.010 0.121
P
b 0.266 0.646 0.729 0.277 0.635 0.734 0.034 0.257
P
a value for Wilcoxon signed-rank test between breast tumor and adjacent normal tissue. P
b value for Wilcoxon signed-rank test between breast tumor and
adjacent normal tissue after Benjamini Hochberg correction - significant values shown in bold. a: Number and corresponding percentage of hypomethylated
tumors compared to adjacent normal, b: Number and corresponding percentage of hypermethylated tumors compared to adjacent normal, c: Number and
corresponding percentage of tumors that show same methylation compared to adjacent normal.
Figure 5 Categorization of expression pattern of genes involved in death receptor apoptotic pathway [(TRAIL + DR4 + DR5 + CASP8 +
ATM + H2AX + CHEK2 + CYCS)/(DCR1 + DCR2 + CASP8L + FLIPL + FLIPS + BCL2)] and DNA damage response pathway [ATM + CHEK2 +
BRCA1 + BRCA2 + H2AX], stratified with respect to tumor stage.
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Page 11 of 16response and apoptotic pathway gene methylation pro-
file, we were able to segregate the normal and tumor tis-
sues. Our observation followed by statistical analysis of
methylation status in breast tumors along with tran-
script expression revealed a negative correlation for
TRAIL, DR4, CASP8, ATM, CHEK2, BRCA1 and BRCA2
CpG sites. Insilico analysis of these methylated CpG
sites/units revealed the presence of consensus sequence
for stimulatory protein 1 (Sp1) and estrogen receptor
(ER) transcription factors. Studies have revealed that
methylated CpGs in these recognition sites preclude the
binding of the Sp1 transcription factor and thereby inhi-
bit gene expression directly [55,56]. DNA methylation
has also been shown to be followed by binding of
methyl-CpG binding domain proteins (MBDs) which
contribute to gene repression by the recruitment of his-
tone deacetylases (HDACs) to nucleosomes [57]. The
CpG sites within CHEK2 and BRCA2 were observed to
be the consensus sequence for Sp1; whereas such sites
in TRAIL, DR4, CASP8, ATM and BRCA1 did not have
transcription factor binding sites. We believe methyla-
tion of these sites might inhibit/promote the binding of
Sp1/MBDs, respectively to the methylated DNA, result-
ing in decreased gene expression.
For the first time, our study showed a collaborative
involvement of DR5, DCR1, DCR2, CASP8, CYCS,
BRCA1, BRCA2, H2AX hypermethylation and DR4,
FLIP, RNF8 hypomethylation in sporadic breast tumor
pathogenesis. Since apoptotic signaling through DR5 has
been reported to be more potent than through DR4
[58], our data suggests that hypermethylation status of
DR5 receptor facilitates tumor cells to evade apoptosis.
Despite the hypomethylation state of DR4 receptor and
hypermethylation state of anti-apoptotic decoy receptors
(DCR1 and DCR2) [25,42,43], we propose that the final
outcome in tumor pathogenesis depends on downstream
signal transduction molecules, such as CASP8, FLIP and
CYCS in established tumors. Hypermethylation of
CASP8 and hypomethylation of FLIP inhibits the extrin-
sic apoptotic pathway, whereas hypermethylation of
CYCS suggests a weak activation of intrinsic apoptotic
pathway. Similarly, hypermethylation of BRCA1, BRCA2
and H2AX implies a decreased DNA damage repair.
This is in accordance with the knowledge that inhibition
of DNA damage response and apoptosis may contribute
to tumor initiation, growth and metastasis in the patho-
genesis of breast cancer [59,60].
We believe decoy receptor down-regulation through
hypermethylation in initial (stages I and II) as well as
advanced stages (stage III and IV) represents a ‘physiolo-
gical’ response to check the conversion of precancerous
cell to a cancerous one by enhancing apoptosis, which
can be evaded by established tumors via mechanisms
such as aberrant methylation of DDR and apoptotic
genes. The methylation profiles of the candidate genes
in this pathway revealed increased apoptosis in initial
tumors (T1 and T2) as a result of hypomethylated DR4
which initiates the death receptor signal transduction
pathway in response to TRAIL. Although in initial
tumors (T1 and T2) hypermethylation of DR5 and
hypomethylation of FLIP i so b s e r v e d ,w eb e l i e v e ,t h e
positive feedback loop due to hypomethylated ATM is
strong enough to override the antiapoptotic effect of
FLIP thereby enhancing DR4 mediated apoptosis. How-
ever, in advanced tumors (T3 and T4) most of the
methylation profiles observed in initial tumor stages are
lost consequently, resulting in decreased apoptosis.
Hypermethylation of DR5 in grade III tumors also
Table 4 Correlation of methylation of tumor samples with respect to the transcript expression
SR.
NO.
GENE CpG SITE/UNIT (N = 40) SPEARMAN’S RHO (r) CORRELATION
COEFFICIENT
P
a LOCATION TRANSCRIPTION FACTOR (TF)
BINDING SITE
1 TRAIL TRAIL 9 (-116) -0.350 0.013 Promoter No
2 DR4 DR4 10.11.12.13 (+23,+25,
+28,+32)
0.335 0.017 5’UTR GBF2
3 DR4 DR4 7 (+108) -0.311 0.025 5’UTR No
4 CASP8 CASP8 5 (+571) -0.271 0.046 Int 1-2 No
5 CYCS CYCS 36.37 (+241,+243) 0.266 0.048 Int 1-2 Sp1
6 ATM ATM 1 (-369) -0.270 0.046 Promoter No
7 ATM ATM 7.8 (-314,-310) -0.291 0.034 Promoter No
8 CHEK2 CHEK2 3.4 (-396,-393) -0.281 0.040 Promoter Sp1
9 BRCA1 BRCA1 8 (-314) -0.300 0.030 Promoter No
10 BRCA1 BRCA1 16 (-251) -0.410 0.004 Promoter No
11 BRCA2 BRCA2 44 (-101) -0.288 0.036 Promoter Sp1
12 BRCA2 BRCA2 15.16.17 (+133,+136,
+138)
-0.318 0.023 5’UTR ER, Sp1
P
a value for Spearman’s rho correlation coefficient.
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sive form of breast tumors. In the context of TRAIL
mediating the activation of DNA damage response path-
way [28,29], hypermethylation of BRCA2 (stage III and
IV) indicated an aberrant DNA damage repair mechan-
ism in response to TRAIL mediated apoptosis. Thus our
study showed a deregulation of death receptor apoptosis
and DDR pathway genes through methylation, influen-
cing breast tumorigenesis; also indicated by reduced
apoptosis and DNA repair in advanced tumor. This is in
accordance with the fact that suppression of apoptosis
and DNA damage repair comprise the minimum com-
mon platform upon which all neoplastic evolution
occurs [61]. We suggest that besides genetic aberrations
of DDR-apoptotic genes, their deregulated methylation
also plays an intricate role in tumor development. On
the whole, the study revealed cooperative involvement
of the DDR and apoptotic genes at the level of methyla-
tion in assisting tumor cell survival and progression by
apoptotic evasion and loss of DNA repair during spora-
dic breast tumor progression (Figure 7).
In addition, BRCA2 germline variation concomitant
with the presence of methylation in the promoter region
was novel and interesting and emerged as a strong can-
didate for susceptibility to sporadic breast tumors. Fla-
nagan et.al. [21] showed in familial breast cancers that
methylation profiles are defined by mutation status. On
the basis of BRCA2 -26 GA heterozygotes observed ear-
lier by us with a protector genotype, showing decreased
LOH; and the risk providing GG/AA homozygotes
showing increased LOH [6], we suggest that the pre-
sence of hypermethylated DR5, CASP8, BRCA2 and
Table 5 Comparison of mean methylation between normal and tumor samples for the 17 genes studied with respect
to the BRCA2 -26 5’UTR polymorphism
GENES BRCA2 -26 GG + AA (N = 54) BRCA2 -26 GA (N = 27)
METHYLATION PERCENTAGE P
a P
b METHYLATION PERCENTAGE P
a P
b
TRAIL 26
a,2 6
b,2
c 48%
a, 48%
b,4 %
c 0.655 0.696 14, 10, 3 52%, 37%, 11% 0.555 0.858
DR4 31, 21, 2 57%, 39%, 4% 0.033 0.070 16, 11, 0 59%, 41%, 0% 0.175 0.595
DR5 14, 37, 3 26%, 69%, 6% 0.001 0.006 11, 15, 1 41%, 56%, 4% 0.394 0.837
DCR1 18, 36, 0 33%, 67%, 0% 0.0001 0.001 11, 16, 0 41%, 59%, 0% 0.038 0.215
DCR2 12, 41, 1 22%, 76%, 2% 0.0000002 0.000003 4, 22, 1 15%, 81%, 4% 0.0008 0.014
CASP8 20, 32, 2 37%, 59%, 4% 0.006 0.026 11, 15, 1 41%, 56%, 4% 0.970 0.970
BCL2 29, 24, 1 54%, 44%, 2% 0.972 0.972 12, 15, 0 44%, 56%, 0% 0.914 1.036
FLIP 32, 19, 3 59%, 35%, 6% 0.009 0.026 13, 14, 0 48%, 52%, 0% 0.952 1.012
CYCS 25, 29, 0 46%, 54%, 0% 0.164 0.253 8, 19, 0 30%, 70%, 0% 0.139 0.591
ATM 30, 22, 2 56%, 41%, 4% 0.303 0.429 13, 12, 2 48%, 44%, 7% 0.443 0.837
TP53 18, 33, 3 33%, 61%, 6% 0.029 0.070 14, 12, 1 52%, 44%, 4% 0.334 0.811
BRCA1 19, 35, 0 35%, 65%, 0% 0.065 0.123 15, 12, 0 56%, 44%, 0% 0.648 0.918
BRCA2 15, 34, 5 28%, 63%, 9% 0.008 0.027 9, 14, 4 33%, 52%, 15% 0.273 0.774
CHEK2 23, 25, 6 43%, 46%, 11% 0.320 0.418 12, 14, 1 44%, 52%, 4% 0.829 1.084
TIP60 28, 21, 5 52%, 39%, 9% 0.466 0.528 13, 12, 2 48%, 44%, 7% 0.893 1.084
RNF8 28, 24, 2 52%, 44%, 4% 0.454 0.551 18, 9, 0 67%, 33%, 0% 0.025 0.213
H2AX 17, 34, 3 31%, 63%, 6% 0.152 0.258 13, 12, 2 48%, 44%, 7% 0.535 0.910
P
a value for Wilcoxon signed-rank test between breast tumor and adjacent normal tissue. P
b value for Wilcoxon signed-rank test between breast tumor and
adjacent normal tissue after Benjamini Hochberg correction - significant values shown in bold. a: Number and corresponding percentage of hypomethylated
tumors compared to adjacent normal, b: Number and corresponding percentage of hypermethylated tumors compared to adjacent normal, c: Number and
corresponding percentage of tumors that show same methylation compared to adjacent normal.
Figure 6 Comparison of mean methylation of BRCA2 gene with
its transcript expression (r: spearman’s correlation coefficient).
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Page 13 of 16hypomethylated FLIP with BRCA2 -26 GG or AA geno-
type, might cause increased LOH, decreased DNA repair
and apoptosis, providing a risk for sporadic breast
tumor development and progression. These observations
allow us to assign an important role to a concomitant
presence of variant germline genetic background at
5’UTR of BRCA2 and the epigenetic modification in the
process of oncogenesis.
No genome-wide evaluation have been carried out to
identify altered DNA methylation patterns in the con-
text of tumor initiation and/or progression [62] and
their effects on DNA damage response - apoptotic path-
way or gene networks. Our study indicates that promo-
ter methylation of DDR-apoptotic genes in sporadic
breast cancer is not a random phenomenon. It has two
features: hypermethylation of DDR-apoptotic genes, and
hypomethylation of anti-apoptotic/pro-survival genes.
Progressive modification of the aberrant epigenetic
alterations with advancing tumors results in deregula-
tion of the DDR-apoptotic pathway thereby promoting
tumor development. We also observe BRCA2 to play a
major role at both genetic and epigenetic level in spora-
dic breast tumor pathogenesis. We propose, since patho-
logical epigenetic changes of the DDR-apoptotic genes
are reversible modifications [63], these could further be
targeted for therapeutic interventions.
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